Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: JOHN W. who wrote (2671)	11/6/1997 6:49:00 PM
From: tommysdad	Read Replies (1) \| Respond to of 6136

Who's David Crossen? <eom>

To: JOHN W. who wrote (2671)	11/7/1997 10:57:00 AM
From: Peter Silsbee	Read Replies (3) \| Respond to of 6136

(1) "Anyone who shares David Crossen's view on the lifespan of Viracept which at this time is their only marketed drug is negative on the company's fundamentals." (2) "It would appear a lot of people on these threads are investing/or shorting Viracept not Agouron Pharmaceuticals. Viracept is only the first chapter of Agourons story. Yeah, it is a great beggining...but the huge profits will be in the future. Were these two comments really written by the same person?